EICHORCondition: Lung Cancer, Non-Small Cell · Sponsor: GlaxoSmithKline
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Fountain Valley, California, United States | — |
| GSK Investigational Site | Walnut Creek, California, United States | — |
| GSK Investigational Site | Norwich, Connecticut, United States | — |
| GSK Investigational Site | Washington D.C., District of Columbia, United States | — |
| GSK Investigational Site | Honolulu, Hawaii, United States | — |
| GSK Investigational Site | Iowa City, Iowa, United States | — |
| GSK Investigational Site | Edgewood, Kentucky, United States | — |
| GSK Investigational Site | Las Vegas, Nevada, United States | — |
| GSK Investigational Site | Mineola, New York, United States | — |
| GSK Investigational Site | New York, New York, United States | — |
| GSK Investigational Site | White Plains, New York, United States | — |
| GSK Investigational Site | Pittsburgh, Pennsylvania, United States | — |
+ 151 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04655976